Articles tagged with Drug Studies
Researchers found lamotrigine to reduce stiffness in non-dystrophic myotonias by around the same amount as mexiletine, offering a new treatment option. The trial results have direct implications for patient care and provide more 'real-world' options for patients with this life-changing muscle disorder.
A new study reveals how psilocybin alters brain connectivity to alleviate symptoms of body dysmorphic disorder, potentially aiding treatment. Psilocybin strengthens neural connections between executive functions and emotionally salient stimuli, leading to improved BDD symptoms.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
Researchers confirm that fibrosis in HER2-negative breast tumors is associated with an adverse prognosis and better treatment outcomes with nintedanib. A new test, MeCo Score, analyzes gene activity related to fibrosis and indicates the effectiveness of supplementing chemotherapy with antifibrotic therapy.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
Researchers found a significant reduction in nosebleed severity, fewer transfusions, and improved quality of life in patients with hereditary hemorrhagic telangiectasia treated with pomalidomide. The trial's results offer hope for people with this rare bleeding disorder.
A recent clinical trial found that an IV iron treatment called ferric carboxymaltose works faster and better than oral iron tablets in treating anaemia during pregnancy. The study showed improved haemoglobin levels and iron correction with the IV treatment, with comparable side effects.
Researchers found pomalidomide to be safe and effective in reducing nosebleed severity, improving quality of life, and decreasing the need for blood transfusions in adults with hereditary hemorrhagic telangiectasia. The trial stopped early due to successful findings, offering a promising treatment option for this rare bleeding disorder.
A clinical trial found that an oral cancer drug reduced nosebleed severity and improved quality of life in patients with hereditary hemorrhagic telangiectasia (HHT). The PATH-HHT study showed significant improvements in disease manifestations, including severe nosebleeds and chronic gastrointestinal bleeding.
A systematic review of studies on antiseizure drugs in men with epilepsy suggests that there is no clear evidence of a detrimental impact on offspring outcomes. While some isolated harmful side effects were found, they were not replicated in other investigations. The review casts doubt on the stance taken by the UK drugs regulator and ...
Researchers discovered a novel treatment that extends ovarian function in older mice by improving maintenance of the ovaries and preventing key age-related changes. The treatment also fixes hormone production and overall health, alleviating symptoms such as bone loss, cardiovascular disease, and cognitive decline.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
A drug that delivers chemotherapy directly to tumors has shown substantial and durable activity in treating brain metastases of HER2-positive breast cancer. The treatment, trastuzumab deruxtecan, has improved progression-free survival and objective response rates in patients with advanced disease.
A post-hoc analysis of the SURMOUNT trials found that tirzepatide consistently reduced body weight in both males and females, but women experienced greater weight loss with up to 24.6% reduction compared to 18.1% for men. The safety profile was broadly similar by sex, but females were more likely to experience nausea and vomiting.
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques. The researchers found that higher levels of a critical brain protein correlate equally well with cognitive benefits.
A researcher has developed a novel drug delivery system that transports medications to the inner ear to prevent cisplatin-induced hearing loss. The system uses hydrogels and nanoparticles to deliver drugs that block calcium damage or protect hair cells, showing promising results in early-stage studies.
A phase 1 trial found that a new oral weight loss drug, Amycretin, resulted in significant weight loss of up to 13% over three months. The drug targets both amylin and glucagon-like peptide-1 (GLP-1) biology, leading to appetite regulation and reduced hunger.
Researchers have developed a semaglutide hydrogel that could reduce diabetes shots to once a month, improving drug adherence and quality of life. The hydrogel's slow release of semaglutide over one month was found to be well-tolerated in laboratory rats with no inflammatory reactions.
Researchers developed a gene therapy that restored useful vision to most patients with Leber congenital amaurosis type I, a rare inherited blindness. The treatment showed a 10,000-fold improvement in light sensitivity and improved navigation abilities in patients who received the highest dose.
A clinical trial led by Washington University School of Medicine found that two anti-coagulant drugs did not improve outcomes for patients who received vessel-clearing interventions after a blood clot in the brain. The study aimed to test whether adding these medications could prevent further clots, but results showed no benefit.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
A novel low-dose 3-in-1 blood pressure pill (GMRx2) significantly reduces blood pressure in patients with uncontrolled hypertension. After six months treatment, the GMRx2 group achieved a 5.8mmHg lower systolic blood pressure compared to standard care.
New studies show semaglutide reduces all-cause death, CV death, and non-CV death in people with overweight or obesity and established cardiovascular disease. The medication also improves heart failure symptoms and physical limitations in those with obesity-related HFpEF, regardless of sex.
A study emulated a clinical trial using real-world UK healthcare data to explore treatment effects in patients with atrial fibrillation. The method found similar outcomes between apixaban and warfarin, but with differences linked to ethnicity and medication use.
A new study published in Alzheimer's & Dementia found that cholinesterase inhibitors (ChEIs) may slow down cognitive decline in dementia with Lewy bodies over five years. ChEIs were also associated with a reduced risk of death in the first year after diagnosis.
A new non-hormonal hot flash treatment has been shown to significantly reduce symptom frequency and severity within weeks, while also improving sleep quality and overall well-being. The investigational drug elinzanetant was found to have a favorable safety profile with mild side effects.
A new study found that semaglutide significantly reduces major adverse cardiac events, including heart attacks and strokes, among overweight individuals with cardiovascular disease. The medication also shows similar benefits for people with pre-existing heart failure, regardless of type or severity.
A team of neuroscientists at Stanford University discovered that blocking the kynurenine pathway can improve cognitive function in lab mice with Alzheimer’s disease. The study found that drugs that block this pathway improved glucose metabolism, corrected astrocytic performance, and enhanced spatial memory in the mice.
A WVU researcher argues that more validation is needed for the increasing number of gallbladder surgeries performed for biliary dyskinesia, a functional gallbladder disorder. The researcher suggests that a combination of factors must come together to diagnose and select patients who would benefit from surgery.
A clinical study confirmed the safety of aceneuramic acid in treating distal myopathy with rimmed vacuoles (GNE myopathy), a rare disease causing progressive muscle weakness. The treatment, developed for an ultra-orphan drug, showed efficacy and was approved by Japan's Ministry of Health, Labour and Welfare.
A disproportionality analysis of World Health Organization data revealed a signal of semaglutide-associated suicidal ideation, particularly among patients with co-reported antidepressant use. This finding warrants urgent clarification and highlights the need for further research on the safety profile of semaglutide.
Researchers at UCSF have developed intelligent brain pacemakers that use AI to monitor and adjust brain activity in real-time, providing personalized treatment for Parkinson's patients. The approach, called adaptive deep brain stimulation, has shown promise in reducing symptoms such as movement problems and insomnia.
A new study by Northwestern University found that PrEP users frequently perceive others using the medication as promiscuous, despite knowing those who use it. The authors suggest sex-positive messaging to address this stigma and encourage a broader understanding of PrEP's benefits among vulnerable populations.
A study examining tecovirimat's effectiveness on mpox in the DRC found the drug safe but showed no significant impact on lesion duration. The trial, sponsored by the NIH and co-led with the DRC, resulted in lower mortality rates among participants compared to reported cases.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A new study provides first-of-its-kind data on the pharmacokinetics and safety of intravenous remdesivir in treating SARS-CoV-2 coronavirus in pregnant women. The research reveals that no dose adjustments are necessary for remdesivir when used in pregnant women, with no safety concerns or adverse pregnancy outcomes identified.
A study by researchers at São Paulo State University found that dopaminergic medication levodopa improves sleep quality in Parkinson's disease patients. The number of times patients woke up during the night fell by 25% and the amount of time they remained awake fell 30% on average.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
Research by University of Southampton finds medications improve ADHD quality of life, but core symptoms targeting alone is insufficient; combining medication with other approaches may lead to further improvements in well-being.
A clinical study in Birmingham has found that nipocalimab can improve the survival rate of unborn babies with rare fetal anaemia. The majority of pregnant patients who received nipocalimab gave birth at or after 32 weeks without needing an intrauterine transfusion, resulting in a perinatal survival rate of 92%.
Results of a Phase 2 clinical trial show that nipocalimab can delay or prevent anemia and intrauterine blood transfusions in babies at high risk for Hemolytic Disease of the Fetus and Newborn (HDFN). The study involved 13 pregnant women who received intravenous nipocalimab between 14 and 35 weeks of gestation.
Researchers question the effectiveness of new amyloid immunotherapy drugs in reducing Alzheimer's disease impact, citing limited eligibility and high costs. The drugs showed small effect sizes that may not outweigh the risk of adverse events.
A nationwide study found that brentuximab vendotin significantly improved the quality of life for young patients with high-risk pediatric Hodgkin lymphoma. Nearly 44% of patients reported poor quality of life before treatment, but researchers saw significant improvement as treatment progressed.
A major new study by Karolinska Institutet has found that women with epilepsy are four times more likely to die during pregnancy and their babies have a 50 percent higher risk of illness or death. Despite the high relative risks, most pregnancies for women with epilepsy go well.
Researchers at WashU Medicine have developed a novel compound that effectively clears bacterial infections in mice, including those causing rare and potentially fatal 'flesh-eating' illnesses. The compound targets gram-positive bacteria, reducing virulence and speeding up post-infection healing.
A new study found that Cannabigerol (CBG) significantly reduced feelings of anxiety at 20, 45 and 60 minutes after ingestion, with stress ratings also decreasing. CBG's effect on memory was unexpectedly positive, enhancing the ability to recall lists of words.
Terasaki Institute scientists have created a novel bioink derived from egg whites, offering abundant proteins and excellent biocompatibility. This breakthrough technology has the potential to create more accurate tissue models for drug testing and develop functional tissue replacements for regenerative medicine applications.
US adolescents have reported decreases in both medical and nonmedical use of prescription medications between 2009 and 2022. The study attributes these changes to factors such as revised prescribing guidelines and COVID-related school closures.
Researchers study T cells and monocytes interaction in the meninges before they attack the brain and spinal cord, potentially leading to new disease progression targets. The findings could provide a pathway to treating other neurological diseases like Alzheimer's and Parkinson's.
The A4 study, a large clinical trial of pre-symptomatic Alzheimer’s disease, has yielded key insights into the condition. Researchers have collected extensive data on brain scans, blood samples, genetic information and cognitive tests from over 7,500 participants.
A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.
A new study published in Neurology found that ofatumumab is more effective than teriflunomide at helping people with relapsing-remitting MS reach a period of no disease activity across racial and ethnic groups. The medication showed consistent results among diverse populations, including Black, Hispanic, and Asian individuals.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
A new study published in Hypertension journal suggests that both 30-year and 10-year risk predictions should be considered when making high blood pressure treatment decisions. The researchers compared two risk prediction tools and found that long-term, 30-year risk may be more important than short-term, 10-year risk for informing medic...
TAS-303 reduces SUI episode frequency by 58% compared to placebo, while also improving urinary incontinence amount and health-related quality of life. The medication may offer a safer alternative for SUI treatment without adverse effects associated with existing medications.
Researchers analyzed over 1.5 million patient records to find that metformin and SGLT-2 inhibitors lowered dementia and Alzheimer's disease risks compared to other antidiabetic drugs. The study suggests individualized treatment approaches considering patient-specific factors for optimal diabetes management.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.